11 February 2020

Oviva raises USD 21M to roll out digital diabetes treatment in Europe.

The round was led by Swiss healthtech investor MTIP, joined by Earlybird as new investors. Existing investors AlbionVC, F-Prime Capital, Eight Roads Ventures and Partech all participated. Oviva offers an evidence-based digital solution to stop the progression of reverse Type 2 diabetes and obesity-related conditions. Patients receive tailored nutrition advice and personalised coaching via their phones.

VISCHER advised the new investors in this financing round. The team was led by Dr. Matthias Staehelin (Corporate / M&A) and included Nadia Tarolli (Tax), Luzius Zumstein (Corporate / M&A), Sebastian Flückiger and Pauline Pfirter (Corporate / M&A).

Press release

Categories: Health Care, Life Sciences, Pharma, Biotech, Private Equity & Venture Capital, Startup Desk

You are currently offline. Some pages or content may fail to load.